What is Aptevo Therapeutics Inc's earnings per share (EPS)?

Aptevo Therapeutics Inc (APVO) reported diluted earnings per share of $-87.27 for fiscal year 2025. This represents a 0.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Aptevo Therapeutics Inc Financials

APVO

Source SEC Filings (10-K/10-Q) Updated Mar 26, 2026 Currency USD FYE March

This page shows Aptevo Therapeutics Inc (APVO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

1.06x

For every $1 of reported earnings, Aptevo Therapeutics Inc generates $1.06 in operating cash flow (-$25.6M OCF vs -$24.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$26.1M

YoY-7.5%

Aptevo Therapeutics Inc's EBITDA was -$26.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 7.5% from the prior year.

Net Income

-$24.1M

YoY+0.0%

Aptevo Therapeutics Inc reported -$24.1M in net income in fiscal year 2025. This represents an increase of 0.0% from the prior year.

EPS (Diluted)

$-87.27

YoY+0.1%

Aptevo Therapeutics Inc earned $-87.27 per diluted share (EPS) in fiscal year 2025. This represents an increase of 0.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

YoY-19.0%

Aptevo Therapeutics Inc had 1M shares outstanding in fiscal year 2025. This represents a decrease of 19.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$14.5M

YoY+1.1%

5Y CAGR-4.0%

10Y CAGR-8.3%

Aptevo Therapeutics Inc invested $14.5M in research and development in fiscal year 2025. This represents an increase of 1.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

APVO Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	$3.1M-74.7%	$12.3M+185.3%	$4.3M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$14.5M+1.1%	$14.4M-16.0%	$17.1M-4.3%	$17.9M-5.9%	$19.0M+6.4%	$17.9M
SG&A Expenses	$11.8M+15.1%	$10.2M-13.1%	$11.8M-15.2%	$13.9M-5.6%	$14.7M+5.4%	$14.0M
Operating Income	-$26.3M-7.0%	-$24.6M+14.8%	-$28.9M-0.8%	-$28.6M-33.8%	-$21.4M+22.2%	-$27.5M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$24.1M0.0%	-$24.1M-38.6%	-$17.4M-316.9%	$8.0M+128.2%	-$28.5M-60.3%	-$17.8M
EPS (Diluted)	$-87.27+0.1%	$-87.38	$-2316.83	$1.57+125.9%	$-6.07	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$4.0M+21.5%	$3.3M-8.4%	$3.6M	N/A	$3.1M-14.8%	$3.6M-2.9%	$3.8M	N/A
SG&A Expenses	$3.6M+23.1%	$2.9M+1.8%	$2.8M	N/A	$2.1M-11.4%	$2.4M-26.3%	$3.2M	N/A
Operating Income	-$7.6M-22.2%	-$6.2M+3.9%	-$6.5M	N/A	-$5.2M+13.5%	-$6.0M+13.7%	-$7.0M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$7.5M-21.7%	-$6.2M+3.2%	-$6.4M	N/A	-$5.1M+13.3%	-$5.9M+13.9%	-$6.8M	N/A
EPS (Diluted)	$-2.23	$-8.40-91.3%	$-4.39	N/A	$-357.86+71.1%	$-1236.96-235.9%	$-368.21	N/A

APVO Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$15.6M-37.2%	$24.8M-27.4%	$34.2M-39.6%	$56.6M+5.7%	$53.5M
Current Assets	N/A	$10.7M-44.1%	$19.1M-30.5%	$27.4M-47.8%	$52.6M+11.2%	$47.3M
Cash & Equivalents	N/A	$8.7M-48.5%	$16.9M-25.3%	$22.6M-49.7%	$45.0M+12.7%	$40.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$10.8M-14.1%	$12.6M-22.3%	$16.2M-70.7%	$55.4M+49.9%	$37.0M
Current Liabilities	N/A	$6.2M-14.1%	$7.2M-17.0%	$8.7M-75.0%	$34.8M+139.1%	$14.5M
Long-Term Debt	N/A	N/A	$0-100.0%	$1.5M-60.7%	$3.7M-86.9%	$28.2M
Total Equity	N/A	$4.8M-61.1%	$12.2M-32.0%	$18.0M+1378.1%	$1.2M-92.7%	$16.6M
Retained Earnings	N/A	-$247.6M-10.8%	-$223.4M-8.5%	-$206.0M+3.7%	-$214.1M-15.3%	-$185.6M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$27.0M+72.8%	$15.6M+87.3%	$8.3M-46.5%	$15.6M+2.9%	$15.1M+1.5%	$14.9M-15.4%	$17.6M-29.0%	$24.8M
Current Assets	$22.6M+104.4%	$11.1M+207.2%	$3.6M-66.2%	$10.7M+6.5%	$10.0M+4.5%	$9.6M-20.7%	$12.1M-36.7%	$19.1M
Cash & Equivalents	$21.1M+123.8%	$9.4M+339.9%	$2.1M-75.5%	$8.7M+12.4%	$7.8M-3.9%	$8.1M-21.3%	$10.3M-39.4%	$16.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$9.6M+5.5%	$9.1M-7.3%	$9.8M-9.4%	$10.8M+1.0%	$10.7M+2.6%	$10.5M-9.3%	$11.5M-8.7%	$12.6M
Current Liabilities	$5.6M+14.8%	$4.9M-9.3%	$5.4M-13.1%	$6.2M+5.5%	$5.9M+8.5%	$5.4M-14.0%	$6.3M-12.8%	$7.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Total Equity	$17.4M+166.6%	$6.5M+542.9%	-$1.5M-131.0%	$4.8M+7.6%	$4.4M-1.0%	$4.5M-26.9%	$6.1M-50.1%	$12.2M
Retained Earnings	-$269.2M-3.5%	-$260.2M-2.4%	-$254.0M-2.6%	-$247.6M-2.6%	-$241.3M-2.2%	-$236.2M-2.6%	-$230.3M-3.1%	-$223.4M

APVO Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$25.6M-7.6%	-$23.8M-102.8%	-$11.7M+44.2%	-$21.0M+3.0%	-$21.7M+26.1%	-$29.3M
Capital Expenditures	N/A	N/A	N/A	$29K-95.9%	$713K+710.2%	$88K
Free Cash Flow	N/A	N/A	N/A	-$21.1M+6.0%	-$22.4M+23.9%	-$29.4M
Investing Cash Flow	N/A	$0	$0+100.0%	-$29K+95.9%	-$713K-102.5%	$28.0M
Financing Cash Flow	$38.5M+146.9%	$15.6M+160.0%	$6.0M+329.3%	-$2.6M-110.0%	$26.2M+9.6%	$23.9M
Dividends Paid	$1.5M	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$6.7M+5.7%	-$7.1M-7.9%	-$6.6M-14.2%	-$5.8M-10.3%	-$5.2M+15.1%	-$6.2M+7.5%	-$6.7M-26.6%	-$5.3M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$18.3M+27.7%	$14.4M	$0-100.0%	$6.7M+36.9%	$4.9M+23.7%	$4.0M+132400.0%	-$3K-100.1%	$3.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

APVO Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	-919.8%-745.6pp	-174.1%+464.0pp	-638.1%
Net Margin	N/A	N/A	N/A	257.8%+489.3pp	-231.5%+180.4pp	-411.9%
Return on Equity	N/A	-507.5%-365.0pp	-142.5%-187.1pp	44.7%+2384.9pp	-2340.2%-2233.2pp	-107.0%
Return on Assets	N/A	-154.8%-84.7pp	-70.1%-93.5pp	23.5%+73.7pp	-50.3%-17.1pp	-33.1%
Current Ratio	N/A	1.72-0.9	2.64-0.5	3.15+1.6	1.51-1.7	3.25
Debt-to-Equity	N/A	2.28+2.3	0.00-0.1	0.08-3.0	3.05+1.3	1.70
FCF Margin	N/A	N/A	N/A	-676.0%-493.8pp	-182.2%+500.3pp	-682.4%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-43.4%+51.7pp	-95.1%	N/A	N/A	-115.4%+16.4pp	-131.8%-19.8pp	-112.0%	N/A
Return on Assets	-28.0%+11.8pp	-39.7%+37.1pp	-76.8%	N/A	-33.7%+5.8pp	-39.4%-0.7pp	-38.8%	N/A
Current Ratio	4.03+1.8	2.27+1.6	0.67-1.0	1.72+0.0	1.70-0.1	1.77-0.1	1.92-0.7	2.64
Debt-to-Equity	0.55-0.8	1.39+8.1	-6.66-8.9	2.28-0.1	2.43+0.1	2.34+0.5	1.89+1.9	0.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Xenetic Biosciences Inc XBIO

$6.9M

GRI Bio GRI

$3.4M

Onconetix ONCO

$1.1M

Oragenics OGEN

$2.4M

Quoin Pharmaceuticals Ltd QNRX

$12.7M

Frequently Asked Questions

Is Aptevo Therapeutics Inc profitable?

No, Aptevo Therapeutics Inc (APVO) reported a net income of -$24.1M in fiscal year 2025.

What is Aptevo Therapeutics Inc's EBITDA?

Aptevo Therapeutics Inc (APVO) had EBITDA of -$26.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Aptevo Therapeutics Inc's operating cash flow?

Aptevo Therapeutics Inc (APVO) generated -$25.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

How much does Aptevo Therapeutics Inc spend on research and development?

Aptevo Therapeutics Inc (APVO) invested $14.5M in research and development during fiscal year 2025.

How many shares does Aptevo Therapeutics Inc have outstanding?

Aptevo Therapeutics Inc (APVO) had 1M shares outstanding as of fiscal year 2025.

Are Aptevo Therapeutics Inc's earnings high quality?

Aptevo Therapeutics Inc (APVO) has an earnings quality ratio of 1.06x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.